Startup Scouting for Corporations
|
See Oxford Cannabinoid Technologies's full profile BOOK A DEMO |
| Headquarters United Kingdom |
Founded Year 2017 |
Total Funding
$10.0M |
Employees
11 - 50 |
Status Active |
About Oxford Cannabinoid TechnologiesOCT uses 21st century technology and modern drug development standards to explore the potential of cannabinoid medication and bring pioneering treatments to the market. |
HeadquartersUnited Kingdom |
General Information on Oxford Cannabinoid Technologies
| Brand name | Oxford Cannabinoid Technologies |
| Company name | Oxford Cannabinoid Technologies |
| Website | https://www.oxcantech.com/ |
| Founded year | 2017 |
| Employees | 11 - 50 |
| Contact | [email protected] +4401865304040 |
|
Find startup solutions in your specific business context The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
|
BOOK A DEMO |
Recent News and Activity about Oxford Cannabinoid Technologies |
|
ResearchTree
•
10.12.2021
Oxford Cannabinoid Technologies Holdings expands its reach to US with OTCQB platformOxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) CEO John Lucas tells Proactive it has got the go-ahead for its shares to start trading on the OTCQB Market, the mid-tier OTC Equity Market in the United States. Dual trading of its shares on the London Stock Exchange's Main Market and the OTCQB market will provide enhanced investor benefits, Lucas says, making it including easier access to trading for investors based in the US and increased ... 
|
|
ResearchTree
•
07.12.2021
Oxford Cannabinoid Technologies collaborate with Dalriada to expand into other therapeutic areasDalriada has previously designed, synthesised and experimentally tested all of the compounds in the Canopy library. |
|
Wiredfocus
•
01.12.2021
London's Oxford Cannabinoid Technologies to launch twin US listingInvestors were seemingly pleased with the move, as OCTP's share price surged 17.9 per cent by mid-afternoon. Landing on the US' OTC Equity Market under the ticker OCTHF, the cannabinoid pharmaceutical firm said that the new listing will open it up to a “broader pool of potential investors” which will bolster liquidity. OCTP's assured London shareholders that its ability to trade its existing ordinary shares on the London Stock Exchange's (LSE) ... 
|
|
City A.M.
•
01.12.2021
London’s Oxford Cannabinoid Technologies to launch twin US listingLondon-listed Oxford Cannabinoid Technologies (OCTP) is set to open a twin listing in the US to ensure investors have “easier access”. Investors were seemingly pleased with the move, as OCTP’s share price surged 17.9 per cent by mid-afternoon. Landing on the US’ OTC Equity Market under the ticker OCTHF, the cannabinoid pharmaceutical firm said that the new listing will open it up to a “broader pool of potential investors” which will bolster ... 
|
|
Market Watch
•
01.12.2021
Oxford Cannabinoid Technologies Shares Rise on US OTC Market Listing ApprovalShares of Oxford Cannabinoid Technologies Holdings PLC rose as much as 14% in early trade Wednesday after the company said that its application for trading on the U.S. OTC QB Market has been approved. The cannabinoid-focused pharmaceutical company backed by tobacco group Imperial Brands PLC and rapper Snoop Dogg, which floated on the London Stock Exchange in May, said that the U.S. listing will provide enhanced investor benefits, including ... 
|
|
Swissquote (Switzerland) (German)
•
24.11.2021
BRIEF-Oxford Cannabinoid Technologies Holdings Says Gavin Sathianathan To Retire From Board With Immediate EffectNov 24- Oxford Cannabinoid Technologies Holdings PLC:* OXFORD CANNABINOID- DIRECTORATE CHANGE |
|
MarketScreener
•
18.11.2021
Oxford Cannabinoid Technologies Holdings plc Announces New Agreement Signed with Oxford Stemtech Limited | MarketScreenerOxford Cannabinoid Technologies Holdings plc announced that OCT has signed a new drug development agreement with Stemtech. Stemtech is a contract research organisation based in Oxford and led by Dr. Zameel Cader, which generates re-programmed human stem cells for research and drug discovery. Under the agreement Stemtech will provide OCT with cutting edge support for its drug development programmes, starting with Programmes 3 and 4 which are ... 
|
|
ResearchTree
•
18.11.2021
Oxford Cannabinoid Technologies in drug development deal with Oxford StemTechUsing cell technology pioneered by Professor Zameel Cader and his team, Sowemimo-Coker said the aim is to predict in the lab human responses to OCT’s cannabinoid-based treatments using re-engineered stem cells. |
|
Proactive Investors
•
01.11.2021
Proactive News round-up: Oxford Cannabinoid Technologies, MGC Pharmaceuticals Ltd, Westmount, Challenger Energy …Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP) said 198.5mln of its shares, representing 20.7% of the company's issued share capital, have been pledged as security against a loan by Kingsley Capital Partners, a partnership controlled by its executive chairman, Neil Mahapatra. IXICO PLC (AIM:IXI, OTC:PHYOF) has been chosen by its largest pharma client to provide neuroimaging services for a new phase III clinical trial into demyelinating ... 
|
|
Proactive Investors USA
•
15.10.2021
Oxford Cannabinoid Technologies on progress since listing, including Canopy Growth Corporation dealIt captures the period that led to its stock market float on May 21, as it raised £16.5mln of new equity to fund the business’s development.The company has inked agreements with key partners for its lead cannabis drug compound as well as its drug-device/phytocannabinoid combination. It has also acquired key medical assets from Canopy Growth Corporation( TSX:WEED, NYSE:CGC ) (TSX:WEED, NYSE:CGC ), giving it an exclusive worldwide licence to their ... 
|
Footer
About INNOSPOT
